These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16895217)

  • 1. [PPARgamma-activating properties of angiotensin receptor blockers].
    Ando H; Fujimura A
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():498-501. PubMed ID: 16895217
    [No Abstract]   [Full Text] [Related]  

  • 2. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
    Pershadsingh HA
    Int J Biochem Cell Biol; 2006; 38(5-6):766-81. PubMed ID: 16298156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
    Doggrell SA
    Curr Opin Investig Drugs; 2005 Mar; 6(3):242-4. PubMed ID: 15816499
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
    Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
    Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?
    Ernsberger P; Koletsky RJ
    Curr Opin Pharmacol; 2007 Apr; 7(2):140-5. PubMed ID: 17303473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan - killing two birds with one stone.
    Doggrell SA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2397-400. PubMed ID: 15500387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential effects of angiotensin II receptor blockers on glucose tolerance and adiponectin levels in hypertensive patients.
    Makita S; Abiko A; Naganuma Y; Moriai Y; Nakamura M
    Cardiovasc Drugs Ther; 2007 Aug; 21(4):317-8. PubMed ID: 17629779
    [No Abstract]   [Full Text] [Related]  

  • 8. New treatment strategies for patients with hypertension and insulin resistance.
    Kurtz TW
    Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].
    Ariyoshi Y; Mizumoto K
    Nihon Yakurigaku Zasshi; 2009 May; 133(5):275-80. PubMed ID: 19443965
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of high-normal blood pressure with angiotensin receptor blockers. TROPHY Study (Trial of Preventing Hypertension)].
    Mann J
    Internist (Berl); 2007 Apr; 48(4):436-8. PubMed ID: 17342351
    [No Abstract]   [Full Text] [Related]  

  • 11. [The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
    Ohashi H; Takagi H
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():297-301. PubMed ID: 15999723
    [No Abstract]   [Full Text] [Related]  

  • 12. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological and clinical properties of AIMIX® combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate].
    Mori M; Takahashi S
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):39-46. PubMed ID: 23842227
    [No Abstract]   [Full Text] [Related]  

  • 14. Does the PPAR-γ-activating property of telmisartan provide a benefit in clinical practice?
    Fujimura A; Ushijima K; Ando H
    Hypertens Res; 2013 Feb; 36(2):183. PubMed ID: 23190691
    [No Abstract]   [Full Text] [Related]  

  • 15. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers.
    Kintscher U; Unger T
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S26-32. PubMed ID: 15868116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In the DETAIL. Kidney protection in manifestations of microalbuminuria].
    MMW Fortschr Med; 2006 Jun; 148(26):51. PubMed ID: 16875382
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypertension after kidney transplantation: still a SECRET?
    Lopau K; Wanner C
    Nephrol Dial Transplant; 2010 Mar; 25(3):664-5. PubMed ID: 20042402
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin receptor antagonists.
    Wong W; Howes L
    Aust Fam Physician; 2000 Jul; 29(7):653-5, 658. PubMed ID: 10914449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
    Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
    Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating prehypertension.
    Conen D; Martina B
    N Engl J Med; 2006 Jul; 355(4):417; author reply 417-8. PubMed ID: 16871687
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.